Commercial Services Segment by Services to Account Larger Share in Pharmaceutical Contract Sales Organizations Market during 2022–2030

According to our latest study on “pharmaceutical contract sales organizations market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis" the market is expected to grow from US$ 8,212.02 million in 2022 and is expected to reach US$ 15,820.86 million by 2030; it is anticipated to record a CAGR of 8.6% from 2022 to 2030. The report highlights the key factors driving the pharmaceutical contract sales organizations market growth and prominent players with their developments in the market.

Pharmaceutical companies may outsource their sales and marketing functions to third parties, commonly referred to as contract sales organizations, under the pharmaceutical contract sales outsourcing (CSO) business model. Because of the financial benefits, the improved flexibility, and the easy access to specialized knowledge, this practice has gained popularity in the pharmaceutical sector. Companies that manage contract sales teams also offer training, hiring, and performance evaluation. Contract sales outsourcing does, however, come with some drawbacks, including the potential loss of sales process control and the requirement to uphold solid vendor relationships.

The pharmaceutical contract sales organizations market: by service, is segmented into commercial services and non-commercial services. In 2022, the commercial services segment held the largest share of the market and is expected to grow at the fastest rate during the coming years. Commercial services refer to the range of services provided by contract sales organizations (CSOs) to pharmaceutical companies to support their sales and marketing efforts. CSOs are third-party organizations specializing in delivering sales and marketing services on behalf of pharmaceutical companies.

The pharmaceutical contract sales organizations market, by module, is segmented into syndicated modules and dedicated modules. In 2022, the syndicated modules segment held the largest share of the market and is expected to grow at the fastest rate during the coming years. Syndicate modules refer to a collaborative approach where multiple pharmaceutical companies join forces to share resources and expertise in order to achieve common sales and marketing goals. These modules allow the companies to form a unified team that promotes and sells the products of all participating companies.

The pharmaceutical contract sales organizations market, by therapeutic area, is segmented into cardiovascular disorders, oncology, metabolic disorders, neurology, orthopedic diseases, infectious diseases, and others. In 2022, the oncology segment held the largest share of the market. Oncology is one of the world's fastest-moving therapeutic areas, and it is expected to represent a major part of pharmaceutical sales in the future, creating a growing demand for pharmaceutical contract sales outsourcing in the oncology therapeutic area.

The pharmaceutical contract sales organizations market, by end user, is segmented into biopharmaceutical companies and pharmaceutical companies. In 2022, the pharmaceutical companies segment held the largest share of the market.

CMIC Holdings Co., Ltd., Axxelus, EPS Holdings, Inc., MaBico, IQVIA, Inc., Peak PharmA, QFR Solutions, Promoveo Health, Syneous Health Inc., Mednext Pharmaceuticals Pvt. Ltd are among the leading companies operating in the global Diabetic Foot Ulcer market.    

Companies operating in the pharmaceutical contract sales organizations market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies in the breast cancer therapeutics market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall pharmaceutical contract sales organizations market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below.

• In September 2021, Leading contract research business (CRO) PRA Health Sciences was acquired by ICON plc. ICON's position in the CRO market is anticipated to improve as a result of the acquisition.
• In September 2022, pharmaceutical organization Dr. Reddy's Laboratories partnered with IQVIA, Inc. In accordance with the arrangement, IQVIA gave Dr. Reddy's access to its Orchestrated Customer Engagement (OCE) platform to assist with its CRM operations. According to the deal, Dr. Reddy's gave IQVIA's OCE application to all its marketing users and field staff in India so they could more effectively engage customers by integrating marketing, account management, medical scientific liaison, sales, and other activities.
• In November 17, 2020, Expert Medical Navigation (EMN), a provider of medical affairs solutions for pharmaceutical firms, was acquired by PDI. The acquisition is anticipated to increase PDI's capacity for medical affairs.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com